183 related articles for article (PubMed ID: 30942056)
1. The Role of
Cengiz A; Koç ZP; Özcan Kara P; Yürekli Y
Mol Imaging Radionucl Ther; 2019 Mar; 28(1):8-14. PubMed ID: 30942056
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
7. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
8. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
11. Clinical Value of Combining
Sookha RR; Zhi W; Shen Y; Lazare C; Wang L; Meng Y; Cao C; Hu J; Wu P
J Cancer; 2018; 9(17):3101-3108. PubMed ID: 30210633
[No Abstract] [Full Text] [Related]
12. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
13. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
15. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
16. Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.
Capitanio S; Bongioanni F; Piccardo A; Campus C; Gonella R; Tixi L; Naseri M; Pennone M; Altrinetti V; Buschiazzo A; Bossert I; Fiz F; Bruno A; DeCensi A; Sambuceti G; Morbelli S
World J Radiol; 2016 Feb; 8(2):200-9. PubMed ID: 26981229
[TBL] [Abstract][Full Text] [Related]
17. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
20. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.
Picchio M; Mangili G; Samanes Gajate AM; De Marzi P; Spinapolice EG; Mapelli P; Giovacchini G; Sigismondi C; Viganò R; Sironi S; Messa C
Nucl Med Commun; 2010 Jun; 31(6):506-12. PubMed ID: 20168262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
